Recently, E2F function has expanded to include the regulation of differentiation in human epidermal keratinocytes (HEKs). We extend these findings to report that in HEKs, Sp1 is a differentiation-specific activator and a downstream target of E2F-mediated suppression of the differentiation-specific marker, transglutaminase type 1 (TG-1). Deletion of elements between À0.084 to À0.034 kb of the TG-1 promoter disabled E2F1-induced suppression of promoter activity. Electrophoretic mobility shift assays (EMSAs) demonstrated that Sp1 and Sp3 bound this region. Protein expression analysis suggested that squamous differentiation was accompanied by increased Sp1/Sp3 ratio. Cotransfection of proliferating HEKs or the squamous cell carcinoma (SCC) cell line, KJD-1/SV40, with an E2F inhibitor (E2Fd/n) and Sp1 expression plasmid was sufficient to activate the TG-1 promoter. The suppression of Sp1 activity by E2F in differentiated cells appeared to be indirect since we found no evidence of an Sp1/E2F coassociation on the TG-1 promoter fragment. Moreover, E2F inhibition in the presence of a differentiation stimulus induced Sp1 protein. These data demonstrate that (i) Sp1 can act as a differentiation stimulus, (ii) E2F-mediated suppression of differentiation-specific markers is indirect via Sp1 inhibition and (iii) a combination of E2F inhibition and Sp1 activation could form the basis of a differentiation therapy for SCCs.
Introduction
Squamous differentiation is coordinated by a tightly controlled transcriptional programme, which involves regulation by multiple transcription factors such as AP1, Sp1, AP2 and E2F (Eckert et al., 1997a; Dicker et al., 2000a; Popa et al., 2004) . The initial step in this differentiation programme is the irreversible growth arrest of keratinocytes in the basal layer of the epithelium. Once growth arrested, keratinocytes begin to differentiate and migrate through the suprabasal layers, altering both morphologically and biochemically. These biochemical changes can be used to distinguish between the processes of keratinocyte proliferation and squamous differentiation. Squamous differentiation is accompanied by the suppression of proliferation-specific genes such as p53 (Woodworth et al., 1993) , cdk1 (Dahler et al., 1998) and keratin 14 (Lane et al., 1985) . Simultaneously, differentiation-specific genes such as transglutaminase type 1 (TG-1) keratin 10 and cornifin are induced (Eckert et al., 1997a, b) . Disruption of proliferation control and differentiation invariably accompanies the development of squamous cell carcinoma (SCC). Therefore, treatments aiming to inhibit the aberrant proliferation of neoplastic cells while simultaneously reinstating a normal differentiation programme would be invaluable. In order to develop such 'differentiation therapies', it is important to identify the molecular cues that control squamous differentiation.
In previous studies, we reported that the transcription factor family, E2F, may play a dual role in promoting keratinocyte proliferation as well as suppressing squamous differentiation (Dicker et al., 2000a; Wong et al., 2003 Wong et al., , 2004 . Currently, there are seven known members of the E2F family, E2F 1-7 (Trimarchi and Lees, 2002; Di Stefano et al., 2003) . E2F 1-6 exist in a heterodimeric complex bound with a dimeric partner protein, DP1 or DP2 (Trimarchi and Lees, 2002) , while E2F7 requires no heterodimeric partner (Di Stefano et al., 2003) . E2Fs can act as both trans-activators and/or repressors. For instance, the 'free' E2F complex (i.e. E2F/DP complex) is able to trans-activate proliferation-specific E2F-responsive genes, while binding of the E2F complex to hypophosphorylated forms of pocket proteins (pRb, p107 or p130) represses transcriptional activity of these same target genes. Specifically, different E2F members preferentially bind to different pocket proteins. For example, E2Fs 1-3 bind pRb, E2Fs 4-5 bind p107 and E2F5 binds p130 (Weinberg, 1995) . The regulation of E2F-responsive genes by pocket proteins is considered to occur by two distinct mechanisms: (a) by active inhibition such that E2F is unable to activate transcription or (b) by active repression in which the E2F-pocket protein complex recruits cofactors, such as histone deacetylases and histone methyltransferases, that lead to transcriptional repression (Trimarchi and Lees, 2002) . Although knowledge of how E2Fs regulate proliferation is relatively well understood, the mechanism by which E2Fs modulate squamous differentiation appears novel and cell cycle independent. The importance of E2Fs as modulators of differentiation has only recently been appreciated. For example, E2Fs are now recognized to be involved in the differentiation of a variety of cell types such as myocytes (Wang et al., 1995) , megakaryocytes (Guy et al., 1996) and adipocytes (Fajas et al., 2002) . Although the nature of the involvement of E2F in the differentiation of these cell types is still under investigation, it is likely that the underlying mechanisms are complex, varied and cell-type specific. For instance, E2F1 and E2F4 are proposed to act antagonistically in regulating terminal adipocyte differentiation such that E2F4 serves to maintain differentiation (Fajas et al., 2002) , whereas in keratinocytes, E2F inhibition is a prerequisite for differentiation; yet, once a cell differentiates, E2Fs 1-5 (not E2F6) are all able to suppress differentiation-specific markers (Wong et al., 2003 .
We have previously proposed a model in which E2F has a dual role in keratinocyte proliferation and squamous differentiation (Wong et al., 2003 . Since E2F is able to suppress multiple markers of squamous differentiation and is able to suppress differentiation induced by multiple differentiation-inducing stimuli (Dicker et al., 2000a; Wong et al., 2003) , this would suggest that E2F has the capacity to act as a global regulator of squamous differentiation. In the first instance, E2F has a proproliferative role that is cell cycle dependent. Secondly, E2F inhibition is an essential prerequisite to suppress proliferation and to 'sensitize' a cell to differentiation stimuli . Finally, once a keratinocyte is growth arrested and committed to squamous differentiation, E2F assumes an alternate role as a modulator of this process. The basis for the proposition that E2F plays a role in E2F-mediated modulation of squamous differentiation is supported by the following observations: (i) E2Fs are expressed in differentiated keratinocytes, (ii) E2Fs 1-5 suppress differentiation markers, (iii) inhibition of E2F superinduces/derepresses differentiation marker activity in differentiated cells, (iv) E2F inhibition is not sufficient to initiate squamous differentiation and (v) squamous differentiation can be reinstated in a differentiationresistant SCC cell line following E2F inhibition and provision of a differentiation stimulus (Wong et al., 2003 . However, the identities of the 'factors' that mediate E2F regulation of squamous differentiation are currently unknown. In order to identify these 'factors', we examined the molecular basis of this suppression using the well-characterized differentiation-specific marker, TG-1.
Results
E2F-mediated suppression of squamous differentiation is mediated through an Sp1 site in the TG-1 promoter
The ability of E2F family members to suppress the activity of differentiation-associated markers in keratinocytes has been reported previously (Dicker et al., 2000a; Wong et al., 2003) . In the present study, we show that overexpression of E2F1 significantly reduced the activity of established differentiation-specific reporter genes, TG-1 Luc and K10-Luc, in confluent, differentiated keratinocytes (Figure 1a) .
In order to understand how E2F suppresses squamous differentiation, we examined the effects of E2F1 on the TG-1 promoter. Using a series of 5 0 deletion constructs, all regions of the TG-1 promoter between À2.9 and À0.084 kb were suppressed by E2F1 overexpression. However, this sensitivity to E2F1 was lost when the region between À0.084 and À0.034 kb of the TG-1 promoter had been removed (Figure 1b ). These data suggest that the region between À0.084 and À0.034 kb of the promoter contains response elements that are sensitive to E2F1-mediated suppression of TG-1 promoter activity.
The DNA-binding properties of the 50 bp fragment located between À0.084 and À0.034 kb in the TG-1 promoter (known to contain an Sp1 site) were examined by electrophoretic mobility shift assays (EMSAs). Three specific complexes were apparent within this region (Figure 2a ). These complexes were competed for by the TG-1 Sp1 oligonucleotide, indicating that an active-Sp1 site is present within this region. The three complexes were unaltered when competed with the nonspecific cdxA oligonucleotide and the mt-Sp1 oligonucleotide. Competition by the consensus Sp1 oligonucleotide eliminated all specific DNA-binding complexes, demonstrating that the only detectable binding site within this promoter region is an Sp1 site (Figure 2b ). While the À0.084 to À0.034 kb promoter fragment did not contain a consensus E2F binding site, it remained possible that the suppression by E2F represented competition for an overlapping nonconsensus E2F binding site. However, competition analysis using a consensus E2F site revealed no ability to compete for specific binding, indicating that the mechanism by which E2F suppresses TG-1 is not through direct binding to the TG-1 promoter (Figure 2b ). Together with the reporter assays, our data suggest that E2F1-induced suppression of TG-1 Luc activity is mediated through elements located between À0.084 and À0.034 kb of the promoter, where only an Sp1 site is detected.
Supershift analysis using Sp1-Sp4 antibodies indicated that the TG-1 promoter region between À0.084 and À0.034 kb contained Sp1 and Sp3 protein binding complexes (Figure 2c ). This finding was confirmed using chromatin immunoprecipitations (ChIP) assays (Figure 2d ). We were not able to produce supershift analysis using the Sp4 antibody, even in COS-1 nuclear extracts transfected with Sp4 (data not shown). Similarly, the Sp4 antibody did not work in ChIP assays. Our results suggest that Sp1 and Sp3 proteins are involved in the regulation of TG-1 promoter activity in differentiated cells. Furthermore, these data indicate that suppression of the TG-1 promoter, by E2F1, is mediated through an Sp1 site located between À0.084 and À0.034 kb of the promoter, where Sp1 and Sp3 are bound. These data also suggest that Sp1/Sp3 may be important regulators of TG-1 transcription and squamous differentiation in general.
Expression of Sp1 family members in cultured keratinocytes, SCC cell lines and tissue sections
If the Sp1 family of transcription factors were to be physiologically relevant regulators of squamous differentiation and the target of E2F-mediated suppression, examination of expression levels may give insight into the relevant Sp1 isoforms involved in the process. Whole-cell extracts were blotted and probed with Sp1-Sp4 antibodies (Figure 3a) . Results from these experiments showed that Sp1, Sp3 and Sp4 were expressed in both proliferating and confluent (differentiated) keratinocytes. Moreover, squamous differentiation of keratinocytes was accompanied by a marked increase in the expression ratio of Sp1 to Sp3. This observation is consistent with previous reports (Apt et al., 1996) . Sp2 was not expressed in HEKs, which was consistent with the absence of DNA binding in the supershift assays. Sp4 expression was similar in both proliferating and differentiated keratinocytes (Figure 3a) .
The increase in Sp1/Sp3 expression ratio in differentiated keratinocytes was verified by immunohistochemical staining of normal human foreskin (Figure 3b ). While Sp1 staining was present throughout the epidermis, staining was more intense in the upper suprabasal layers. In contrast, Sp3 staining was more prominent in the basal, proliferating layer of the epidermis. In both instances, staining was restricted to the nuclei. Similar to the Western blot data, in vivo staining for Sp1 and Sp3 suggested that squamous differentiation was accompanied by an increase in the Sp1/Sp3 ratio ( Figure 3b ). Together, these data support the proposition that Sp1 may be an activator of differentiation-specific genes. This is consistent with, and supported by, earlier reports that Sp1 and Sp3 have opposing actions (Lania et al., 1997) .
SCC cell lines are characterized by deregulated proliferation (accompanied by overexpressed E2F1) and insensitivity to differentiation-inducing agents (Dicker et al., 2000b) . If squamous differentiation of keratinocytes is indeed characterized by an increase in the expression ratio of Sp1 to Sp3, we would predict that in SCCs, disruption of this ratio would be observed. SCC cell lines expressed Sp1 and Sp3 in proliferating and differentiated extracts; however, an increased ratio of Sp1 to Sp3 in confluent cells was not consistently observed ( Figure 4a ). Immunohistochemical staining of tongue-derived SCC tumours yielded similar results with extensive staining of both Sp1 and Sp3 throughout the lesion but with no distinct differences between basal and suprabasal layers ( Figure 4b ). These data indicate that the increased expression of Sp1 to Sp3 that accompanies squamous Figure 1 E2F-mediated suppression of squamous differentiation is lost between À0.084 and À0.034 kb of the TG-1 promoter. Confluent cultures of HEKs were transfected with a luciferase reporter linked to the (a) keratin 10 promoter (K10-Luc) or (a and b) TG-1 promoter (TG-1 Luc). Each construct was cotransfected with a b-actin CAT reporter, to correct for transfection efficiency, as well as either the E2F1 expression plasmid ( þ ) or pCDNA3 expression control (À). Data normalized to compare with pCDNA3 control and presented as mean7s.e.m. of triplicate determinations of at least three experiments (* ¼ Po0.05 compared to pCDNA3 control). (b) Data are also represented as the percentage of E2F1 compared to control at each deletion of the TG-1 promoter: 2.9, full length TG-1 promoter; 2.5, from 2.5 kb TG-1 promoter; 1.5, from 1.5 kb TG-1 promoter; 0.35, from 0.35 kb TG-1 promoter; 0.084, from 0.084 kb TG-1 promoter; 0.034, from 0.034 kb of TG-1 promoter; pGL2, luciferase construct Sp1 is a differentiation stimulus upon E2F inhibition CF Wong et al differentiation in normal HEKs is absent in SCC cells. This is consistent with the proposition that Sp1 may act as a differentiating factor in keratinocytes. These data also suggest that loss of appropriate Sp1 regulation may contribute to the differentiation incompetence of SCCs.
Sp1 is the downstream effector for E2F-mediated suppression of squamous differentiation
If Sp1 behaves as an activating transcription factor of differentiation-specific marker genes, we would predict that inducing Sp1 activity in growth-inhibited cells would suffice to evoke squamous differentiation in Figure 3 Expression of Sp1 family members in keratinocytes. (a) Proliferative (prol) and differentiated (conf) keratinocytes were harvested, total cellular protein extracted and 40 mg protein subjected to Western blot analysis for the expression of Sp1-Sp4. (b) Immunohistochemical staining of human neonatal foreskins using the Sp1 and Sp3 antibodies (1/40 antibody dilution). Nonspecific staining was accounted for using the IgG (rabbit) antibody. The expression of b-tubulin was used to determine loading differences between the different samples Figure 2 Loss of E2F-mediated suppression of the TG-1 promoter corresponds with an Sp1 binding site. EMSAs were performed using nuclear extracts from confluent HEKs and 32 P-labelled TG-1 promoter between À0.084 and À0.034 kb. Binding activity was assayed in the absence or presence of 100-fold excess (a) unlabelled TG-1 from À0.084 to À0.034 kb (specific), nonspecific cdxA (nonspecific), the Sp1 site within the À0.084 to À0.034 kb of the TG-1 promoter (TG-1 Sp1), mutated Sp1 site (mt-Sp1) or the (b) consensus Sp1 oligonucleotide (Sp1 consensus) or E2F consensus oligonucleotide (E2F consensus). Specific binding complexes are indicated by the arrows. (c) Supershift of protein complexes were carried out by incubation of reactions with specific antibodies against Sp1-Sp4. Shifted protein complexes are indicated by the arrows. (d) ChIP demonstrating binding of Sp1 and Sp3 to the TG-1 promoter region between À0.084 to À0.034 kb. Free, no nuclear extract binding; confluent, confluent nuclear extract binding to 32 P-labelled TG-1 promoter from À0.084 to À0.034 kb Sp1 is a differentiation stimulus upon E2F inhibition CF Wong et al proliferating keratinocytes. Although overexpression of the E2F dominant-negative construct (E2Fd/n) is able to suppress the promoter activity of known E2F-responsive genes (e.g. cdc2; Figure 5a ) and proliferation-specific markers (Dicker et al., 2000a; Wong et al., 2003 Wong et al., , 2004 , overexpression of E2Fd/n alone or an Sp1 expression plasmid alone in proliferating keratinocytes was not sufficient to induce TG-1 Luc activity ( Figure 5b ). However, a combination of E2F inhibition and Sp1 overexpression in proliferating keratinocytes resulted in an induction of the differentiation-specific marker, TG-1 Luc (Figure 5b ). These data indicate that Sp1 expression alone is not sufficient to initiate differentiation, but if accompanied by E2F inhibition, is capable of inducing differentiation in normal keratinocytes. In this way, Sp1 could be seen as a differentiation effector, independent of the growth inhibitory stimulus (Figure 5c ). We have previously reported that E2F can act as a modulator of squamous differentiation and that inhibition of E2F coupled with exposure to a differentiationinducing agent (such as a phorbol ester) is able to induce the expression of TG-1 in the SCC cell line, KJD-1/ SV40 (Wong et al., 2003) . Hence, it was of interest to determine whether inhibition of E2F coupled with Sp1 overexpression was also sufficient to reinstate TG-1 Luc activity and TG-1 mRNA expression in differentiationincompetent SCCs. In proliferating KJD-1/SV40 cells, overexpression of E2Fd/n or Sp1 alone was not sufficient to induce TG-1 Luc activity (Figure 5d ). However, expression of Sp1 and E2Fd/n concurrently was sufficient to reinstate both TG-1 Luc activity (Figure 5d ) and TG-1 mRNA expression (Figure 5e ) in these cancer cells.
Suppression of the Sp1/Sp3 site by E2F is indirect
The modulation of Sp1 activity by E2F may be mediated via direct and/or indirect mechanisms. To examine the possibility that E2F was directly interacting with, and inhibiting, Sp1/Sp3 at the site of the TG-1 promoter, a biotinylated promoter fragment was used to co-precipitate specific proteins bound to the À0.084 to À0.034 kb region of the TG-1 promoter. These DNAbinding affinity assays revealed that while Sp1 and Sp3 bound to this region, neither E2F1 nor E2F4 could be co-precipitated with them ( Figure 6a ). These data are consistent with the notion that E2F-mediated suppression of the TG-1 promoter is not via a direct association with the Sp1/Sp3 complex. Given that Sp1 is a transactivator of TG-1, we examined the possibility that E2F could suppress the transcription of TG-1 simply by inhibiting Sp1 expression. If this were true, then inhibition of E2F should derepress Sp1 expression and subsequent treatment with a differentiation-inducing stimulus should then induce Sp1 expression. Indeed, overexpression of the E2Fd/n and subsequent treatment with TPA induced the expression of Sp1 in proliferating KJD-1/SV40 cells (Figure 6b ). These data suggest that Sp1 expression is indirectly suppressed by E2F.
Discussion
We have previously reported that E2F can play a role as a physiologically relevant modulator of squamous differentiation (Wong et al., 2003 . However, the downstream transcriptional targets by which E2F mediates suppression of squamous differentiation have not been identified. In the present study, we provide evidence indicating that E2F1-mediated suppression of the differentiation-specific marker, TG-1, is indirectly regulated through an Sp1 site in the TG-1 promoter. This is supported by the following lines of evidence: (i) the ability of E2F1 to suppress the TG-1 promoter was lost in reporter constructs lacking the À0.084 to À0.034 kb region, (ii) a functional Sp1 site was the only binding site found between À0.084 and À0.034 kb in the TG-1 promoter, (iii) Sp1 and Sp3 were bound to this region, but we found no evidence of a coassociation with either E2F1 or E2F4, (iv) the suppression of TG-1, by E2F1, required a DNA-binding domain and transactivation domain (Wong et al., 2003) , yet no evidence of E2F binding to the TG-1 promoter was found and An important conclusion from this study is that Sp1 can act as a differentiation activator and that its activity is regulated by E2F. This differentiation-activating property of Sp1 is supported by the observed increase in the ratio of Sp1 to Sp3 expression that accompanies HEK differentiation, in vitro and in vivo. In addition, the disruption of this ratio in differentiation-impaired SCCs and the ability of Sp1 to induce TG-1, in both normal HEKs and differentiation-incompetent KJD-1/SV40 cells, lends further support to the causal role of Sp1 in squamous differentiation. These data extend earlier reports in which an increase in the Sp1/Sp3 binding activity was observed in differentiated cells derived from mouse keratinocytes, rabbit corneal epithelial cells and transformed keratinocytes (Apt et al., 1996; Chen et al., 1997; Park and Morasso, 1999; Phillips et al., 2004) , and strongly implicates the increase in Sp1/Sp3 ratio as a causal event involved in squamous differentiation. These data also indicate that the disruption of the Sp1/Sp3 ratio in SCC cells may be causally associated with their inability to differentiate. Although an earlier report suggested that the Sp1 site alone contributes only slightly to transcriptional activation of TG-1 (Jessen et al., 2000) , our data show that overexpression of Sp1 is sufficient to induce TG-1 Luc activity in keratinocytes. Moreover, given that functional Sp1 binding sites have been described in the promoters of several other differentiation-specific marker genes (Wu et al., 1994; Lee et al., 1996; Banks et al., 1998; Jang and Steinert, 2002) , our data suggest that Sp1 and E2F are likely to be globally important regulators of differentiation. Combined, these data demonstrate the importance of combinatorial transcriptional control of differentiation genes and how the balance between transcriptional activators and repressors can modulate gene expression.
Our study indicates that squamous differentiation occurs only when (i) E2F-dependent proproliferative activity is suppressed and (ii) differentiation-specific activators, such as Sp1, are activated (Figure 5c ). In proliferating keratinocytes, E2F acts to promote proliferation (Jones et al., 1997; Pierce et al., 1998; Dicker et al., 2000a; Wong et al., 2004) while also restraining the cells from entering a terminal squamous differentiation programme (Wong et al., 2003) . When a growth inhibitory stimulus is perceived, the proproliferative activity of E2F is lost and this sensitizes the keratinocytes to the action of an independent differentiationinducing stimulus (e.g. TPA or confluence). Such a stimulus can then activate differentiation-specific factors such as Sp1, which initiate and maintain squamous differentiation. This model is analogous to the differentiation programme in muscle cells, where MDM2 inhibits Sp1-dependent transcription of muscle cell differentiation-specific genes (Johnson-Pais et al., 2001; Guo et al., 2003) . Hence, a complete differentiation stimulus for the treatment of differentiation-incompetent SCCs would require inhibition of E2F and (Figure 5c ).
The precise mechanism by which E2F inhibits the differentiation-specific activity of Sp1 is unknown. However, our earlier studies have indicated that the DNA-binding domain, trans-activation domain and pocket protein-binding domain of E2F are essential to the suppression of squamous differentiation markers (Wong et al., 2003) . This would suggest that E2F-mediated suppression of Sp1 requires a transcriptionally active E2F. Previously, only E2Fs 1-3, and not E2F4 and E2F5, have been reported to bind directly to Sp1 (Karlseder et al., 1996) . Since E2Fs 1-5 can suppress TG-1 Luc activity (Wong et al., 2003) , a direct interaction between Sp1 and E2F would seem unlikely to be responsible for the suppression of the TG-1 promoter observed in this study. Similarly, it is unlikely that Sp1 and E2F compete for promoter binding sites since we found no evidence of an E2F binding site between À0.084 and À0.034 kb of the TG-1 promoter. This is strongly supported by our failure to detect an interaction between Sp1/Sp3 and either E2F1 or E2F4. Combined, these data suggest that suppression of Sp1 by E2F involves an indirect mechanism in which E2Fs alters Sp1 protein expression levels or activity in a transcription-dependent manner. Although we have modelled our studies on TG-1, numerous differentiation-specific markers (including loricrin, keratin 3, TG-3 and involucrin) also contain functional Sp1 sites, which are essential to the transcriptional control of these genes (Wu et al., 1994; Lee et al., 1996; Banks et al., 1998; Jang and Steinert, 2002) . Thus, it is interesting to speculate that the E2F-mediated suppression of differentiationspecific markers that we observe for TG-1 may be a general mechanism by which E2F regulates squamous differentiation.
Our findings on the role of E2F and Sp1 in the regulation of squamous differentiation in normal keratinocytes have considerable impact on our understanding of the molecular basis of squamous neoplasia. SCCs are characterized by deregulated growth and aberrant differentiation control. In part, disruption to either of these processes could be attributable to the constitutive overexpression of E2F1 observed in SCCs in vitro and in vivo (Jones et al., 1997; Pierce et al., 1998; Dicker et al., 2000a) . Based on our observations, we would predict that E2F overexpression in SCC cells would result in aberrant proliferation and the active suppression of the squamous differentiation programme (Wong et al., 2003 . The present study also indicates that the disruption of proliferation and differentiation in SCCs may also involve the lack of an high Sp1 to Sp3 ratio in SCC cells and tumours. Since Sp3 has been reported to inhibit Sp1-mediated trans-activation (Hagen et al., 1994) , the lack of an high Sp1 to Sp3 ratio in SCCs would be predicted to inhibit the induction of differentiation in these cells. While it is tempting to attribute the lack of differentiation to a relative lack of Sp1, our protein expression analysis would suggest that the defect could also lie with the deregulated overexpression of Sp3 in SCC cells, which would also serve to inhibit Sp1-mediated differentiation. This would be consistent with our observation that Sp1 overexpression could render SCC cells differentiation competent. Whether E2F causally contributes to the disruption of the Sp1 to Sp3 ratio in SCCs is currently unknown.
If defects in Sp1 and E2F regulation were causally associated with SCC development, then one would predict that the inhibition of E2F in conjunction with (i) the reintroduction of Sp1 or (ii) the suppression of Sp3 would reinstate squamous differentiation in SCC cells. To this end, the inhibition of E2F and the introduction of Sp1 in the differentiation-resistant SCC cell line, KJD-1/SV40, resulted in the reinstatement of the differentiation-specific marker, TG-1. This is consistent with our proposition that SCCs are differentiation incompetent due to a combination of constitutive overexpression of E2F and the deregulation of Sp1/ Sp3 resulting in an inability of these neoplastic cells to commit to terminal differentiation. Our data would also predict that the inhibition of E2F alone or the introduction of Sp1 alone would not be sufficient to reinstate squamous differentiation since SCCs are characterized by defects in both E2F and Sp1 regulation. While it has been reported that a combined effect from several transcription factor binding sites, within the TG-1 promoter, is required for maximal gene activation (Medvedev et al., 1999; Phillips et al., 2004) , Figure 6 E2F suppresses TG-1 by an indirect mechanism. (a) Nuclear extracts (1.5 mg) of differentiated keratinocytes were incubated with a biotinylated double-stranded oligonucleotide coding for À0.084 to À0.034 kb region of the TG-1 promoter. Bound proteins were enriched using streptavidin-labelled paramagnetic beads and bound proteins electrophoresed, blotted and probed for Sp1, Sp3, E2F1 and E2F4. (b) Proliferating KJD-1/ SV40 cells were cotransfected with pCDNA3 or E2Fd/n and a red fluorescent protein plasmid (3 : 1 expression plasmid to RFP ratio) and subsequently treated with 50 ng/ml TPA. Transfected cells were sorted by FACS and stained for Sp1 expression. DNA localization was counterstained using DAPI. DAPI, 4 0 ,6-diamidino-2-phenylindole Sp1 is a differentiation stimulus upon E2F inhibition CF Wong et al our results indicate that Sp1 overexpression alone (upon E2F inhibition) is sufficient to induce TG-1 promoter activity and mRNA expression. This suggests that development of a therapy based on a combination of specific E2F inhibitors and Sp1 activators or Sp3 inhibitors could form the basis of an effective differentiation therapy for SCCs.
Materials and methods

Cell culture
Human epidermal keratinocytes (HEKs) were isolated and cultured as described (Jones et al., 1997) . The SCC cell lines, KJD-1/SV40, COLO-16 and SCC25, were cultured as reported (Dicker et al., 2000a) . Growth arrest and differentiation were induced by maintaining confluent cells in culture for 48 h. Contact inhibition induces differentiation in HEKs but not in SCC cell lines (Saunders et al., 1993a, b; Dicker et al., 2000a, b) 
Transfection of cells and reporter assays
The b-actin-CAT (chloramphenicol acetyltransferase) reporter gene and keratin 10 reporter gene (K10-Luc) have been described previously (Rieger and Franke, 1988; Andersen et al., 1993; Dahler et al., 1998) . The cdc2-CAT promoter was a kind gift from Dr Steven Dalton. The b-actin-CAT construct was used to normalize for transfection efficiency. The 2.9 kb TG-1 promoter construct (TG-1 Luc) and the successive promoter deletion constructs (À2.5, À1.5, À0.35, À0.084, À0.034 kb) have been reported previously (Saunders et al., 1993a; Medvedev et al., 1999; Dicker et al., 2000a) . The CMV-E2F1 expression construct was kindly provided by Professor Kristian Helin (Helin et al., 1992) . The CMV-Sp1 (Kadonaga et al., 1987) and CMV-Sp3 (Kingsley and Winoto, 1992) expression constructs were a generous gift from Professor Merlin Crossley. The E2F1 dominant-negative expression construct (E2Fd/n) codes between amino acid 116-235, encompassing the DNA-binding domain and heterodimerization domain of the full-length E2F1 (10).
Cells were transiently transfected in 10 cm 2 wells. Experiments were performed in triplicate and repeated at least twice. Transfection protocols for HEKs (Lipofectaminet, Invitrogen, Australia) and KJD-1/SV40 cells (Effectene, Qiagen, Australia) have been described previously (Dicker et al., 2000a) . Reporter activity was assayed 48 h post-transfection. The luciferase assay protocol has been described (Saunders et al., 1993b; Dahler et al., 1998) . CAT assays were performed utilizing the CAT ELISA kit (Roche, Australia) as per the manufacturer's instructions.
Electrophoretic mobility shift assays
Nuclei were isolated from differentiated HEKs and nuclear extracts prepared as described (Dignam et al., 1983; Medvedev et al., 1999) . A double-stranded oligonucleotide corresponding with À0.084 to À0.034 kb of the TG-1 promoter (5 0 TGGAG CAACCGAGCTTCCCCT; 3 0 TGGGGAGGGCGGGGCCG AGGT) was amplified using specific primers and purified under standard PCR and DNA purification procedures. End labelling of the oligonucleotide probe with [g-32 P]ATP was performed by standard procedures (Medvedev et al., 1999) . Sequences for the double-stranded oligonucleotides, TG-1 Sp1 and mt-Sp1, have been described (Medvedev et al., 1999) . The TG-1 Sp1 oligo (ACCTCGGCCCCGCCCTCCCA) codes for an Sp1 site located 54 bp upstream of the transcriptional start site of the TG-1 promoter. The mt-Sp1 contains two mutations in the Sp1 site (CCCTACCC) and has been demonstrated not to compete for Sp1 DNA binding (Medvedev et al., 1999) . The double-stranded Sp1 consensus oligonucleotide (ATTC-GATCGGGGCGGGGCGAGA) was purchased from Promega (Australia). The double-stranded E2F consensus oligonucleotide (ATTTAAGTTTCGCGCCCTTCTCAAA) has been described previously (Jones et al., 1997) . Nonspecific binding was competed with double-stranded cdxA oligonucleotide (AGATCTGGTACCATTTAAGCCCTCGAGATC TA). Both specific and nonspecific competition was performed with 100-fold excess of the appropriate unlabelled oligonucleotide. Antibodies against Sp1 (sc-59), Sp2 (sc-643), Sp3 (sc-644) and Sp4 (sc-13109) were purchased from Santa Cruz Biotechnology Inc. (Monarch Medical, Australia) .
Approximately 20 000 c.p.m. of [g-32 P]ATP labelled probe was incubated with 1 mg of nuclear extract and binding buffer containing 20 mM HEPES (pH 7.9), 50 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulphonyl fluoride (PMSF) and 10% glycerol (final concentration). In addition, binding reactions contained 1 mg of poly-dIdC and 0.2 mg of salmon sperm DNA to minimize nonspecific binding. For supershift assays, 0.3 or 1 mg of antibody was added to the reaction. Binding reactions were carried out at room temperature for 25 min. DNA-protein complexes were loaded onto a 4% nondenaturing polyacrylamide gel and electrophoresed in 0.5 Â TBE at room temperature. Once dried, the gel was subjected to autoradiography.
Chromatin immunoprecipitation
Confluent HEKs were trypsinized and resuspended in 5 ml of keratinocyte serum-free media. To fix the cellular architecture, 1% formaldehyde was added to the cells over gentle vortex and incubated on ice for 10 min. The fixing reaction was terminated by the addition of 0.125 M glycine and cells were collected by brief centrifugation (1400 r.p.m., 3 min). The cell pellet was resuspended in 1 ml of swelling buffer (10 mM K þ acetate, 15 mM Mg 2 þ acetate, 0.1 M Tris (pH 7.6), 0.5 mM PMSF and 5 mg/ml protease inhibitor cocktail) and incubated on ice for 20 min. Cells were lysed by dounce homogenization with a tight pestle for 30 strokes. Cells were collected by centrifugation (1400 r.p.m., 3 min) and resuspended in sonication buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl (pH 8.1), 0.5 mM PMSF and 100 ng leupeptin and aprotinin). The volume of sonication buffer to resuspend cells was equivalent to 2.5 Â 10 6 cells per 500 ml of buffer. The sample was sonicated on ice three times for 30 s each and the supernatant collected. The supernatant was then incubated for 15 min at 41C with Staph.Aureus protein A beads (40 ml) to remove nonspecific binding. Supernatant was collected and incubated overnight at 41C with either the Sp1 antibody (sc-59), Sp3 antibody (sc-644) or rabbit immunoglobulin as control (sc-2027) from Santa Cruz (Monarch Medical, Australia). A total of 2.5 Â 10 6 cells were incubated with 10, 6, 3 or 1 mg of antibody in order to immunoprecipitate specific proteins.
The following day, 50 ml of preblocked protein A sepharose (P1925, Sigma Aldrich, Australia) was added to the samples and incubated at 41C for 1 h, with rotation. Bound antibodyprotein-DNA interactions were collected by centrifugation at maximum speed for 30 s. An aliquot (5 ml) of the sample was used in PCR to detect the 50 bp region of the TG-1 promoter spanning À0.084 and À0.034 kb. The remaining sample was washed 3 Â in RIPA buffer and subject to SDS-PAGE and Western blotting to detect bound proteins.
Protein isolation and Western blotting
Total cellular protein (40 mg) was subjected to Western blotting as described previously (Khanna et al., 1995) . Sp1 antibody (#07-124) was purchased from Upstate Biotechnology (Auspep, Australia) and a final concentration of 0.5 mg/ml was used to detect expression. Sp2-Sp4 antibodies were purchased from Santa Cruz Biotechnology (Monarch Medical, Australia) and diluted at 1 : 1000 (Sp2, Sp3) and 1 : 200 (Sp4). The b-tubulin antibody was purchased from Sigma Aldrich (T4026) and diluted at 1 : 1000. Immunodetections were visualized after reaction with 1 : 3000 HRP-conjugated goat anti-rabbit and incubation with ECL reagent (Khanna et al., 1995) .
Immunohistochemistry
Paraffin-embedded sections (8 mM) of human neonatal foreskin and human SCCs of the tongue were subjected to antigen retrieval followed by immunohistochemistry as described (Serewko et al., 2002) . Primary antibodies against Sp1 (1 : 40) and Sp3 (1 : 40) were obtained from Santa Cruz Biotechnology (Monarch Medical, Australia). Following primary antibody incubation, slides were washed three times in PBST and secondary antibody (biotinylated goat anti-rabbit; 1 : 1500; Dako, Australia) added for 1 h. Visualization of immunoreactivity utilized horseradish peroxidase-conjugated streptavidin (Dako, Australia) and the chromaphore, diaminobenzidine. Negative controls utilized the rabbit IgG antibody (sc-2027; Monarch Medical, Australia) as primary antibody.
RNA isolation, reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescent-activated cell sorting (FACS) analysis
KJD-1/SV40 cells were transfected as described above, but with the addition of a green fluorescent protein expression plasmid (GFP) at a 1 : 3 ratio with the expression plasmid of interest. At 48 h post-transfection, cells were harvested and GFP-positive cells isolated by FACS (Dahler et al., 2001) . Procedures for total RNA isolation and RT-PCR have been reported previously (Popa et al., 1999; Dahler et al., 2001) . Oligonucleotides for determining TG-1 expression were described previously (Wong et al., 2003) . All amplifications were performed under linear conditions with respect to cycle number (Popa et al., 1999) .
Immunofluorescent staining of KJD-1/SV40 cells KJD-1/SV40 cells were transfected in 25 cm 2 flasks as described above, but cotransfected with a red-fluorescent protein expression plasmid (RFP) at a 1 : 3 ratio with the expression plasmid of interest. At 48 h post-transfection, cells were harvested and RFP-positive cells sorted by FACS (Dahler et al., 2001) . The RFP-positive population of KJD-1/SV40 cells were then grown on coverslips and allowed to recover for 48 h. Cells were washed in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , final pH 7.4) and fixed in 100% cold methanol for an hour at À201C. After two washes in PBS, cells were rehydrated and permeabilized by incubating in 30 mg/ml bovine serum albumin (BSA) supplemented with 0.01% Tween-20 for 1 h at room temperature. Primary antibodies (Sp1 or rabbit IgG as negative control, Santa Cruz, Monarch Medical, Australia) were incubated at 41C overnight (1/100 dilution). Cells were washed three times in PBS supplemented with 0.1% skim milk powder and incubated with the secondary antibody for 1 h (biotinylated rabbit anti-mouse or biotinylated goat anti-rabbit, 1/150; Dako, Australia). Staining was visualized using the streptavidin-fluorescein antibody (1/200, RPN1232, Amersham Biosciences, Australia). Coverslips were mounted using Vectashield s Mounting Medium containing DAPI (4 0 ,6-diamidino-2-phenylindole) to counterstain DNA from Vector Labs (H-1200, Australian Laboratory Services, Australia).
Affinity purification of sequence-specific DNA-binding proteins A biotinylated oligonucleotide corresponding to one strand of the À0.084 to À0.034 kb of the TG-1 promoter was synthesized (Geneworks, Australia), and then annealed to its nonbiotinylated complement by denaturation at 851C for 10 min and annealing of the oligonucleotides by cooling to room temperature. Double-stranded oligonucleotide (0.175 mmol) was incubated with 1.5 mg of confluent HEK nuclear extract in binding buffer containing 20 mM Tris-HCl (pH 7.5), 75 mM KCl, 1 mM DTT, 5 mg/ml BSA and 10% glycerol in the presence of 2 mg of poly-dIdC and incubated at room temperature for 25 min. The specific protein-DNA complexes were enriched using 10 mg of Magnesphere s paramagnetic streptavidin beads (Z5481, Promega, Australia) that were prewashed in 1 Â PBS containing 0.1% BSA. Streptavidin magnetic beads were allowed to bind for 30 min at 41C followed by 10 min at room temperature. The collected beads were washed three times in 2 Â binding buffer and bound proteins were eluted by boiling in sample buffer. Bound proteins were detected by Western blotting. Antibodies were used in a 1 : 1000 dilution and included Sp1 (Upstate Biotechnology, Auspep, Australia), Sp3, E2F1 and E2F4 (Santa Cruz, Monarch Medical, Australia).
